中山长期便血怎么回事(中山痔疮治疗手术多少钱) (今日更新中)

The Washington Post has published what the newspaper describes as the "last piece" written by missing Saudi journalist Jamal Khashoggi, who was allegedly killed and dismembered in his country's consulate in Istanbul earlier this month.In a note at the top of the column, published late Wednesday, Post Global Opinions editor Karen Attiah wrote that she "held off publishing it because we hoped Jamal would come back to us.""Now I have to accept: That is not going to happen," she said. "This is the last piece of his I will edit for The Post. This column perfectly captures his commitment and passion for freedom in the Arab world. A freedom he apparently gave his life for."In the piece, Khashoggi bemoaned the lack of free expression in the Arab world, leaving the majority of its population "unable to adequately address, much less publicly discuss, matters that affect the region and their day-to-day lives." 930

The Washington Redskins are changing their name.According to the Sports Business Journal's John Ourand, the organization will announce the change on Monday. 164

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

The Trump administration is at risk of wasting some of the billions of dollars it wants to spend on the US-Mexico border wall, according to a watchdog report released Monday.The Government Accountability Office concluded that the Department of Homeland Security has not conducted a full analysis of the costs of building the wall. Department officials have also not properly documented their plans for building a portion of wall in the San Diego area.Because of the shortfalls, "DHS faces an increased risk that the Border Wall System Program will cost more than projected, take longer than planned, or not fully perform as expected," GAO wrote.The report also said DHS does not consider costs when deciding where to build. That means it "does not have complete information to determine whether it is using its limited resources in the most cost-effective manner." 872

The U.S. Census Bureau says only a tiny percentage of records are affected by data irregularities that are putting in jeopardy a year-end deadline for turning in numbers used for divvying up congressional seats. However, released internal documents show the "high complexity" problems could push the release to February 2021. The Census Bureau told a congressional committee Thursday that the anomalies are being resolved as quickly as possible. House Democrats however say documents they obtained from Census sources, despite Trump administration stonewalling, show hundreds of thousands of records are affected.Fixing the irregularities could mean missing a Dec. 31 deadline for the Census Bureau to turn reapportionment numbers in to Congress. The internal Census documents shared by House Democrats show the data issues, which include several "high complexity" problems, could delay the once-a-decade report until February. Although the documents do not specify the extent of the larger issues, they do say incorrect handling of the issues could skew the count smaller or larger in some areas. They also say the Census Bureau estimates they need an additional 20 days for data processing. The bureau says the timeline remains in flux.The Census Bureau issued a statement asserting that "these kinds of anomalies and issues are expected and are similar to the Census Bureau's experience in prior decennial censuses." The Census Bureau Director acknowledged the issues in mid-November, more details and the delayed timeline are coming out now. The timeline is getting attention because it may or may not be after President Donald Trump leaves office on January 20. Trump has expressed interest in excluding unauthorized immigrants from the Census count. There have been challenges in court and questions about whether this could legally be done, and also whether it physically can be done by coming up with a reliable number to exclude. Three lower courts have blocked the directive from Trump saying it violates federal law that says the census should could the "whole number of persons" in each state. The Supreme Court just this week heard arguments in the case. They have not issued their ruling yet. 2215

来源：资阳报